New insights into the inter-organ crosstalk mediated by ChREBP

Carbohydrate response element binding protein (ChREBP) is a glucose responsive transcription factor recognized by its critical role in the transcriptional control of glycolysis and lipogenesis. Substantial advances in the field have revealed novel ChREBP functions. Indeed, due to its actions in diff...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in endocrinology (Lausanne) Vol. 14; p. 1095440
Main Authors Carbinatti, Thais, Régnier, Marion, Parlati, Lucia, Benhamed, Fadila, Postic, Catherine
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 27.02.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Carbohydrate response element binding protein (ChREBP) is a glucose responsive transcription factor recognized by its critical role in the transcriptional control of glycolysis and lipogenesis. Substantial advances in the field have revealed novel ChREBP functions. Indeed, due to its actions in different tissues, ChREBP modulates the inter-organ communication through secretion of peptides and lipid factors, ensuring metabolic homeostasis. Dysregulation of these orchestrated interactions is associated with development of metabolic diseases such as type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD). Here, we recapitulate the current knowledge about ChREBP-mediated inter-organ crosstalk through secreted factors and its physiological implications. As the liver is considered a crucial endocrine organ, we will focus in this review on the role of ChREBP-regulated hepatokines. Lastly, we will discuss the involvement of ChREBP in the progression of metabolic pathologies, as well as how the impairment of ChREBP-dependent signaling factors contributes to the onset of such diseases.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Donald Scott, Icahn School of Medicine at Mount Sinai, United States; Joel Haas, INSERM U1011 Récepteurs Nucléaires, Maladies Cardiovasculaires et Diabète, France
Edited by: Nabil Rabhi, Boston University, United States
This article was submitted to Cellular Endocrinology, a section of the journal Frontiers in Endocrinology
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2023.1095440